NCT00586651View on ClinicalTrials.gov

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

September 30, 2010

Conditions
Polycythemia VeraEssential Thrombocytosis
Interventions
DRUG

lestaurtinib

60 mg bid - 120 mg bid for an 18 weeks (126 days) treatment duration

Trial Locations (4)

10021

NY Presbyterian-Cornell, New York

10128

Mount Sinai School of Medicine, New York

19104

University of Pennsylvania, Philadelphia

21231

Johns Hopkins University, Baltimore

Sponsors

Lead Sponsor

Cephalon
All Listed Sponsors
lead

Cephalon

INDUSTRY